- Home
- MRSN vs BWFG Comparison
MRSN vs BWFG Comparison
Compare MRSN & BWFG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRSN
- BWFG
- Stock Information
- Founded
- MRSN 2001
- BWFG 2002
- Country
- MRSN United States
- BWFG United States
- Employees
- MRSN N/A
- BWFG N/A
- Industry
- MRSN Biotechnology: Pharmaceutical Preparations
- BWFG Major Banks
- Sector
- MRSN Health Care
- BWFG Finance
- Exchange
- MRSN Nasdaq
- BWFG Nasdaq
- Market Cap
- MRSN 252.0M
- BWFG 256.5M
- IPO Year
- MRSN 2017
- BWFG N/A
- Fundamental
- Price
- MRSN $1.86
- BWFG $32.83
- Analyst Decision
- MRSN Buy
- BWFG Buy
- Analyst Count
- MRSN 6
- BWFG 1
- Target Price
- MRSN $6.00
- BWFG $40.00
- AVG Volume (30 Days)
- MRSN 1.1M
- BWFG 15.0K
- Earning Date
- MRSN 11-13-2024
- BWFG 01-22-2025
- Dividend Yield
- MRSN N/A
- BWFG 2.42%
- EPS Growth
- MRSN N/A
- BWFG N/A
- EPS
- MRSN N/A
- BWFG 1.94
- Revenue
- MRSN $34,837,000.00
- BWFG $72,009,000.00
- Revenue This Year
- MRSN N/A
- BWFG N/A
- Revenue Next Year
- MRSN N/A
- BWFG $9.07
- P/E Ratio
- MRSN N/A
- BWFG $17.04
- Revenue Growth
- MRSN N/A
- BWFG N/A
- 52 Week Low
- MRSN $1.22
- BWFG $22.47
- 52 Week High
- MRSN $6.28
- BWFG $35.25
- Technical
- Relative Strength Index (RSI)
- MRSN 42.16
- BWFG 51.07
- Support Level
- MRSN $1.93
- BWFG $32.30
- Resistance Level
- MRSN $2.81
- BWFG $33.27
- Average True Range (ATR)
- MRSN 0.24
- BWFG 0.60
- MACD
- MRSN -0.05
- BWFG -0.17
- Stochastic Oscillator
- MRSN 7.79
- BWFG 5.76
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.
About BWFG Bankwell Financial Group Inc.
Bankwell Financial Group Inc is a bank holding company, engaged in providing financial products and services. It offers products related to commercial lending, retail lending, depository services, and others. The bank's commercial lending products includes owner-occupied commercial real estate loans, commercial real estate investment loans, commercial loans to small and mid-sized businesses, and real estate construction and development loans. The retail lending products include residential mortgage loans, home equity lines of credit, and consumer installment loans. Its depository products include checking, savings, money market, certificates of deposit, noninterest-bearing demand, and time deposits.